🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just in The Lancet Oncology The PROs from the EV-302 trial, which led to the global approval of 1L EV+pembro in mUC 👉EV+P led to clinically meaningful pain relief, esp. in pts with moderate-severe baseline pain 👉EV+P led to better EORTC QLQ-C30 functioning and QoL improvements

Congrats @jadchahoud on the terrific talk👉Ab#4515 ASCO #ASCO25 👉Phase 1b STELLAR-002 study of zanzalintinib + nivo +/- relatlimab in pts w/ ccRCC #kidneycancer 👉ORR 63% w/ zanza+nivo (adding relatlimab does not help), key takeaway👇 OncoAlert UroToday.com @KidneyCAN Sumanta K. Pal, MD, FASCO

👉🏻 Tian Zhang, MD, MHS presenting PDIGREE trial update ASCO : PhIII study in 1L metastatic #ccRCC using nivo/ipi → response-adapted treatment (nivo vs cabo vs nivo/cabo). 77% had intermediate-risk IMDC. No new safety signals. Awaiting primary efficacy results. #KidneyCancer #ASCO25

#ASCO2025 Powerful letter from ASCO #DailyNews Editor Neeraj Agarwal, MD, FASCO “In the fight against cancer, we are united by purpose.” Thx for all your hard work & dedication to making this the most valuable free resource for oncology professionals 🌏 by bringing key insights from

🌟Great presentation by Chadi Hage Chehade at #ASCO25!! Utilization and timing of NGS in pts w/ 5 most common cancers in the US👉Many pts either don’t receive NGS or have the first NGS very late 👇ASCO OncoAlert Neeraj Agarwal, MD, FASCO Umang Swami Flatiron Health UroToday.com

👉🏻 Our very own Chadi Hage Chehade presenting ASCO a real-world study showing most patients do not undergo NGS testing, and a substantial proportion receive it only near end of life—limiting its clinical utility and impact on treatment decisions. #ASCO25 GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO

Additive clinical utility of tissue biomarkers of microsatellite instability status and tumor mutational burden to predict immune checkpoint inhibitor effectiveness for real-world patients with #mCRPC. Data show both MSI-high & TMB-high (by FoundationOneCDx) predict improved

Great poster session this morning with Nicolas Sayegh, MD highlighting work in #prostatecancer TMB & MSI-H w/ real world IO outcomes Foundation Medicine! Truly a star resident UTSW Simmons Cancer Center UTSW Internal Medicine co-mentored by me & Neeraj Agarwal, MD, FASCO. Look out for his fellowship apps this fall! #ASCO25

👉🏻 Superstar Zeynep Irem Ozay, MD presenting ASCO our real-world data showing lutetium has better survival outcomes than cabazitaxel in post-ARPI/docetaxel mCRPC patients. #ASCO25 ASCO #ProstateCancer GU Cancer Research Program @HuntsmanCancer Neeraj Agarwal, MD, FASCO OncoAlert UroToday.com

🌟Great poster presentation by Nicolas Sayegh, MD at #ASCO25! Real-world pts with mCRPC👉TMB-H (without MSI-H) & MSI-H have similar outcomes on ICI Flatiron Health MSI-H detected by ctDNA is a predictive biomarker Neeraj Agarwal, MD, FASCO Ryon Graf, PhD Umang Swami UTSW Simmons Cancer Center OncoAlert UroToday.com

Congrats Alicia Morgans, MD, MPH for the outstanding talk ASCO #ASCO25 👉favorable health-related QOL reported by the pts in ph3 ARANOTE trial treated with darolutamide in mHSPC #prostatecancer 👇OncoAlert UroToday.com PCF Science @fredsaad

Leaving Chicago & #ASCO25 with full heart. Reminded of our common purpose to #curecancer and make a difference for our patients. Thanks ASCO for a wonderful data, networking, & inspiration filled weekend!

Best part was seeing mentees past and present Landon C. Brown Chester Kao Charles Jiang MD, MPH Nicolas Sayegh, MD QianJanieQin thriving! #ASCO25

🔥 Ready for next-level RCC insights? Hot off #ASCO25, Dr. Hans Hammers will unpack kidney cancer advances at #WorldGU25. Join us in Nashville, TN, Aug 21–23 for this #CE-accredited event. Register now: hubs.la/Q03qd0T_0 #KidneyCancer #GUOncology #CME

Stellar presentation ASCO #ASCO25 by trailblazer Rana McKay, MD, FASCO on ETCTN trial with radium +|- olaparib in mCRPC #prostatecancer 👉rPFS ⬆️ with the combo w/wo HRRm👇Data continues to reinforce role of PARPi in rationale combinations Toni Choueiri, MD (mentor), UroToday.com OncoAlert

Excited to announce Dr. Benjamin L Maughan as a featured faculty member at #WorldGU25! His expertise in kidney cancer ensures attendees will gain valuable insights from this #CE-accredited conference. Aug 21–23 | Nashville, TN. Don't miss it. Secure your spot now:

Our researchers made a strong showing at #ASCO25 —sharing bold ideas, breakthrough science, and real-world insights to improve cancer care. We’re proud of our team’s dedication to advancing research on a national stage.

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com

Excited to see our work published in Clinical Cancer Research ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇 Grateful for terrific support from team Ryon Graf, PhD Umang Swami Neeraj Agarwal, MD, FASCO UroToday.com OncoAlert

Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer aacrjournals.org/clincancerres/… Research has shown that around 30% of advanced #ProstateCancer patients have Homologous Recombination / DNA Damage